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Abstract We assessed the pretreatment health-
related quality of life (HRQOL) and functional status
of patients with advanced oral and oropharyngeal can-
cer. Eighty patients were investigated. HRQOL was
assessed by EORTC QLQ-C30/QLQ-H&N35 ques-
tionnaires. Functional status assessment comprised
speech and oral function tests. The results revealed a
wide range of HRQOL and functional deWcits before
treatment. HRQOL appeared to be related to some
extent to tumor site (patients with oral tumors
reported more pain compared to patients with oropha-
ryngeal tumors) and tumor classiWcation (patients with
T3–T4 tumors reported more trouble opening the
mouth and felt more ill compared to patients with T2
tumors). Comorbidity appeared to have a major
impact. Patients with comorbidity had signiWcantly
worse scores on several scales/items on both the
EORTC questionnaires. Functional deWcits were
related to tumor site, classiWcation and comorbidity.
Patients with oral cavity tumors (versus oropharyngeal
tumors), patients with T3–T4 tumors (versus T2
tumors), and patients with comorbidity (versus without
comorbidity) scored signiWcantly worse on several
speech and oral function tests. Impaired speech and
oral function appeared to be clearly related to global
quality of life (QLQ-C30) and self-reported speech
(QLQ-H&N35). Many patients with advanced oral and
oropharyngeal cancer have compromised HRQOL and
functional status before the start of treatment. In addi-
tion to tumor site and tumor classiWcation, comorbidity
appears to have a major impact on HRQOL and func-
tional status. Knowledge of pretreatment HRQOL and
functional status levels is useful for better understand-
ing the impact of treatment on these outcomes over
time.
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Introduction
The most important outcome for cancer patients is
overall survival. However, the disease and its treat-
ment often have a major impact on health-related qual-
ity of life (HRQOL) and functional status in patients
with head and neck cancer [1]. Therefore, HRQOL
and functional status are important aspects to consider
in treatment evaluation. To interpret outcome follow-
ing treatment, it is necessary to assess HRQOL and
functional status following diagnosis, but before the
start of treatment [2].
Studies on pretreatment HRQOL [2–5] and func-
tional status [6, 7] often include heterogeneous groups
of head and neck cancer patients. However, there are
substantial diVerences between patient groups that are
related to tumor site and stage [7]. Patients with
advanced oral or pharyngeal cancer, for example, often
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have the poorest HRQOL and functional status [5, 8].
Pretreatment HRQOL among patients with oral or
oropharyngeal cancer is often compromised, although
it tends to be better compared to HRQOL following
treatment [9–11]. There is also evidence that functional
status, including oral function, speech and swallowing
abilities is signiWcantly deteriorated before treatment
[12–15]. Comorbidity is another important factor that
varies substantially among subpopulations of patients,
and can have a signiWcant inXuence on the choice of
initial treatment, the care that patients receive, and on
treatment outcomes [16]. Therefore, comorbidity
should be taken into consideration evaluating the
HRQOL of patients, both at time of diagnosis, and
over the course of treatment [17–19].
The primary objective of the present study is to
assess pretreatment HRQOL and functional status in
relation to tumor site, tumor classiWcation and comor-
bidity, in a well-deWned group of patients with
advanced oral and oropharyngeal cancer.
Patients and methods
Patients
Between January 1998 and December 2001, 92 consec-
utive patients diagnosed with stage II-IV oral or oro-
pharyngeal squamous cell carcinomas were asked to
participate in the study. The planned treatment was
composite resection with microvascular soft tissue
transfer (i.e., radial forearm free Xap) for the recon-
struction of surgical defects, and radiotherapy on indi-
cation. Exclusion criteria were age greater than
75 years, serious cognitive impairment and lack of
basic Xuency in the Dutch language. Twelve patients
declined to participate, resulting in a Wnal sample of 80
patients (response rate = 87%). All patients were
treated at the Department of Otolaryngology/Head
and Neck Surgery of the VU University Medical Cen-
ter, Amsterdam, The Netherlands.
Data collection and study measures
All data were collected prior to the start of treatment,
including sociodemographics (age and gender), disease
stage, comorbidity, HRQOL, and functional status.
Comorbidity was assessed dichotomously (yes or no)
by review of medical records and on the basis of self-
report, and was noted if one or more relevant medical
ailments accompanied the primary medical illness. The
comorbid conditions were cardiovascular, respiratory,
gastro-intestinal, renal, endocrine, neurological, and
immunological disorders, previous malignancy and
considerable weight loss or alcohol abuse. For exam-
ple, cardiovascular problems such as a myocardial inf-
arct or hypertension, respiratory problems such as
restrictive lung disease or COPD, or endocrine disor-
ders such as diabetes mellitus with insulin usage were
deWned as relevant comorbid conditions.
HRQOL was assessed by means of the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 questionnaire (version 2.0) [20]
and the EORTC head and neck cancer module QLQ-
H&N35 [21]. The QLQ-C30 is composed of multi-item
scales and single items assessing Wve areas of function-
ing (physical, role, emotional, cognitive, and social),
fatigue, pain, emesis, dyspnea, insomnia, appetite loss,
constipation, and diarrhea. Overall quality of life and
the perceived Wnancial impact of the disease and treat-
ment are also assessed. The head and neck cancer-spe-
ciWc QLQ-H&N35 module comprises seven symptom
scales: pain, swallowing, senses, speech, social eating,
social contact, and sexuality. There are 11 additional,
single items covering problems with teeth, opening the
mouth wide, dry mouth, sticky saliva, cough, feeling ill,
weight loss, weight gain, use of nutritional supple-
ments, feeding tubes, and painkillers. The scores of
both the QLQ-C30 and of the QLQ-H&N35 are line-
arly transformed to a scale of 0–100, with a higher
score indicating a higher (i.e., more positive) level of
functioning or global HRQOL, or a higher (i.e., more
negative) level of symptoms or problems.
The QLQ-C30 data of the patients were compared
with published normative data from the general popu-
lation of Norway [22]. Comparisons were made with
the normative subsample that corresponded closely to
the age and gender distribution of the patient sample
(i.e., age range of 50–59 years and 48% female). The
QLQ-H&N35 results were compared with reference
values derived from a randomly selected sample of the
Swedish general population [8].
Speech and oral functional status
Speech analyses were performed according to a stan-
dardized speech assessment protocol. Speech record-
ings of a read aloud text were performed in a sound-
treated room and digitized using Cool Edit PRO 1.2
(Adobe Systems Incorporated, San Jose, CA, USA)
with 22 kHz sample frequency and 16 bit resolution.
Recording level was adjusted for each speaker to opti-
mize signal-to-noise ratio. All recordings were made
with a mouth-to-microphone distance of 30 cm. A com-
puter program was developed to perform blinded ran-
domized speech evaluation and to score overallEur Arch Otorhinolaryngol (2007) 264:651–657 653
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intelligibility, and quality of articulation and nasal res-
onance. Overall intelligibility was assessed on a 10-
point scale ranging from poor to excellent by two
trained speech therapists. Scores below six were deW-
ned as insuYcient intelligibility (according to the
Dutch educational system). To obtain more insight
into the cause of decreased intelligibility, evaluation of
the quality of articulation and nasal resonance was per-
formed by the same two speech therapists on a 4-point
scale ranging from deviant (score 1–3) to normal (score
4). Speech rate was measured by calculating words per
minute on a read aloud standardized text.
Oral function was evaluated by a trained investiga-
tor (blinded for the clinical data regarding tumor site
and stage) according to a protocol described by Teichg-
raeber et al. [23]. All assessments were based on 5-
point scales ranging from poor to excellent (trans-
formed scores ranging from 0–100). The oral function
evaluation included three tests; (1) tongue mobility
(mean score of tongue straight out, elevation of tongue
tip, elevation of the base of the tongue, tongue devia-
tion left and right, symmetry left and right, and tongue
withdrawal), (2) lip mobility (mean score of general
movement, spreading and rounding, symmetry left/
right, lip closure without speech, and lip closure during
speaking), and (3) diadochokinesis (mean score of
repetitive motion ability concerning tongue movement
left/right, up/down, and in/out, and repeating the sylla-
bles /ta/ /cha/, and /ka/). Tongue and lip strength were
quantiWed by a calibrated digital voltameter. To mea-
sure tongue strength the patient was asked to push the
tongue against a metallic disc with the lips positioned
around a cylinder, and to resist the force. To measure
lip strength, the patient was asked to keep his lips
around a button with a string attached to it on which
the examiner pulled. Scores ranged from 0 (no
strength) to 0.5 mV (normal strength).
Statistical analyses
Chi-square tests were used to assess associations
between the independent variables tumor site, classiW-
cation and comorbid condition. Student’s t-tests were
performed to test for diVerences between the patient
sample and the normative samples. These tests were
based on the mean scores of the study and normative
samples and the standard deviations of the study sam-
ple only, because no standard deviations of normative
samples were available. Student’s t-tests (HRQOL)
and Mann–Whitney tests (functional status) were per-
formed to determine the impact of tumor site (oral ver-
sus oropharyngeal), tumor classiWcation (T2 versus T3–
T4) and comorbidity (yes or no). Spearman correlation
coeYcients (r) were calculated to investigate the asso-
ciation between self-reported HRQOL (i.e., the QLQ-
C30 global quality of life scale and the QLQ-H&N35
speech scale) and speech and oral functional status.
Statistical signiWcance was deWned as a P-value less
than or equal to 0.05.
Results
Sample description
Patient characteristics are shown in Table 1. The
patients’ age ranged from 23 to 74 years (mean
58 years). Forty-one percent of the sample was female.
One patient was operated on for a recurrent tumor
after prior transoral excision (1 year earlier) in which
the rTNM stage was used, and one patient had under-
gone previous radiotherapy (3 years earlier) for a neck
node of an unknown primary. Four patients had a syn-
chronous second primary tumor, and in these cases the
stage of the largest tumor was used. An equal percent-
age (50%) of patients had a tumor originating on the
left or right side, and in the majority of patients (73%)
the tumor did not extend over the median line. All 80
patients completed the EORTC questionnaires, speech
rate tests (word count) and oral function tests (mobility
and strength). In one patient speech recording could
not be done due to logistical problems, and in three
patients speech recordings were inadequate for inter-
pretation due to technical problems. Speech quality
analyses could thus be performed on 76 patients. Pres-
ence of comorbid conditions and tumor classiWcation
were signiWcantly associated. SigniWcantly more
patients with comorbidity were diagnosed with a larger
tumor (2 =1 0 . 3 7 ,  P < 0.01). No other signiWcant asso-
ciations were observed between tumor site, tumor clas-
siWcation, age, gender and comorbidity.
Health-related quality of life
Compared to the general population, the patients with
oral or oropharyngeal cancer scored signiWcantly worse
on 5 (out of 15) scales or single items regarding the
QLQ-C30: role functioning (P = 0.000), emotional
functioning (P =0 . 0 0 0 ) ,  p a i n  ( P = 0.026), insomnia
(P = 0.016) and appetite loss (P = 0.003). Conversely,
patients scored signiWcantly better regarding social
functioning (P = 0.009), fatigue (P = 0.030), emesis
(P = 0.001), and diarrhea (P = 0.001). Regarding the
QLQ-H&N35, the patients scored signiWcantly worse
on 7 (out of 10) scales or single items compared to the
general population: pain (P = 0.000), swallowing654 Eur Arch Otorhinolaryngol (2007) 264:651–657
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(P = 0.000), senses (P = 0.050), social eating
(P = 0.000), teeth (P = 0.009), opening the mouth wide
(P = 0.000) and sticky saliva (P = 0.005). Conversely,
the patients scored signiWcantly better on two items:
coughing (P = 0.002) and feeling ill (P =0 . 0 2 5 ) .
Regarding tumor site, the QLQ-C30 results were
comparable between oral cavity and oropharynx can-
cer patients. Only the pain score was signiWcantly
worse (P = 0.027) for patients with oral cavity tumors
as compared to patients with oropharynx tumors. The
QLQ-H&N35 also revealed that patients with oral cav-
ity tumors had signiWcantly more pain (P = 0.002); fur-
thermore, problems with their teeth appeared to be
diVerent (P =0 . 0 0 1 ) .
No statistically signiWcant diVerences were observed
for any of the QLQ-C30 scores as a function of tumor
classiWcation (T2 versus T3–T4). Regarding the QLQ-
H&N35, patients with T3–T4 tumors scored signiW-
cantly worse on opening the mouth (P =0 . 0 0 9 )  a n d
reported feeling more ill (P = 0.035) compared to
patients with T2 tumors.
Regarding comorbidity (Table 2), patients with one
or more comorbid conditions scored signiWcantly worse
on QLQ-C30 physical functioning (P = 0.002), global
quality of life (P = 0.016), fatigue (P = 0.014), pain
(P = 0.024), constipation (P = 0.042) and diarrhea
(P = 0.017) compared to patients without comorbidity.
Additionally, based on the QLQ-H&N35 data, patients
with comorbidity reported signiWcantly more pain
(P = 0.007), trouble with social eating (P =0 . 0 3 6 ) ,
teeth problems (P = 0.034), problems with opening the
mouth (P = 0.013) and feeling ill (P = 0.003). The use
of pain medication was signiWcantly higher among
patients with than those without comorbidity (75 ver-
sus 50%; P = 0.025).
Speech and oral functional status
Abnormal scores were observed in 17% of the patients
regarding overall intelligibility, in 25% regarding
nasality and in 37% regarding articulation. Functional
results in relation to tumor site, classiWcation and com-
orbidity are shown in Table 3. Regarding tumor site,
patients with oral cavity tumors scored signiWcantly
worse on intelligibility (P = 0.015), articulation
(P = 0.039), nasality (P = 0.040), tongue and lip mobil-
ity (P = 0.000, 0.009), diadochokinesis (P =0 . 0 0 4 ) ,  a n d
tongue strength (P = 0.001) compared to patients with
Table 1 Characteristics of 80 patients included in this study
Age (years)
Range 23–74
Mean 58
n (%)
Gender
Male 47 (59)
Female 33 (41)
General condition
Comorbidity 48 (60)
No comorbidity 32 (40)
Tumour site
Oral cavity 38 (47)
Oropharynx 42 (53)
T
2 35  (44)
3 42  (52)
4 3  (4)
N
0 24 (30)
1 16 (19)
2a 2 (3)
2b 30 (38)
2c 6 (7)
3 2  (3)
Table 2 EORTC QLQ-C30 and QLQ-H&N35 scores for comor-
bidity
Comorbidity
No Yes
Mean (SD) 
n =3 2
Mean (SD) 
n =4 8
P
EORTC QLQ-C30
Physical functioning 95.0 (12.4) 81.7 (21.4) 0.002
Role functioning 85.4 (18.3) 79.2 (24.9) 0.228
Cognitive functioning 89.6 (18.3) 87.2 (19.2) 0.574
Emotional functioning 69.5 (23.4) 72.2 (24.6) 0.626
Social functioning 93.2 (13.3) 88.5 (21.5) 0.275
Global quality of life 82.6 (19.6) 71.5 (19.7) 0.016
Fatigue 13.9 (20.0) 26.9 (24.1) 0.014
Emesis 1.6 (4.9) 1.4 (4.7) 0.874
Pain 22.4 (25.3) 37.8 (31.8) 0.024
Dyspnea 6.3 (19.7) 10.4 (18.4) 0.338
Insomnia 36.5 (36.3) 31.3 (39.1) 0.550
Appetite loss 7.3 (20.3) 18.7 (31.4) 0.072
Constipation 5.2 (20.9) 18.7 (32.9) 0.042
Diarrhea 1.0 (5.9) 8.3 (16.1) 0.017
Financial impact 2.1 (8.2) 7.6 (20.9) 0.157
EORTC QLQ-H&N35
Pain 27.1 (17.6) 41.5 (25.5) 0.007
Swallowing 14.6 (22.6) 24.1 (22.6) 0.068
Senses 6.3  (14.5) 8.7  (21.5) 0.577
Speech  9.4 (14.1) 13.0 (17.5) 0.336
Social eating 14.6 (25.3) 27.4 (27.1) 0.036
Social contact 3.1 (7.0) 3.7 (6.1) 0.674
Sexuality 16.1 (24.9) 16.3 (27.6) 0.981
Teeth 13.5 (26.6) 30.6 (38.8) 0.034
Opening mouth 7.3 (20.3) 25.7 (37.2) 0.013
Dry mouth 15.6 (26.8) 22.2 (28.6) 0.303
Sticky saliva 12.5 (29.0) 21.5 (31.1) 0.196
Coughing 6.3 (13.2) 14.6 (21.6) 0.055
Feeling ill 0 (0) 9.7 (18.1) 0.003
% Yes % Yes
Pain medication 50.0 75.0 0.022Eur Arch Otorhinolaryngol (2007) 264:651–657 655
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oropharyngeal tumors. Regarding tumor stage,
patients with T3–T4 tumors scored signiWcantly worse
on intelligibility (P = 0.011), articulation (P =0 . 0 0 3 ) ,
tongue mobility (P = 0.001), diadochokinesis
(P = 0.012), and tongue and lip strength (P =0 . 0 2 1 ,
0.018) than patients with T2 tumors. Patients with com-
orbidity scored signiWcantly worse on articulation
(P = 0.043), diadochokinesis (P = 0.026), and tongue
strength (P = 0.045) as compared to patients without
comorbidity.
Correlations between self-report and 
observer rated data
SigniWcant correlations (P < 0.01) were observed
between self-reported global quality of life scale
(QLQ-C30) and observer ratings of intelligibility
(r = 0.41) and articulation (r = 0.36) (Table 4). Addi-
tionally, statistically signiWcant (P < 0.05) but relatively
low correlations were found between self-reported
speech (QLQ-H&N35) and observer ratings of intelli-
gibility (r = ¡0.28), articulation (r = ¡0.24), nasality
(r = ¡0.27) and diadochokinesis (r = ¡0.28).
Discussion
Pretreatment HRQOL and functional status were
investigated in a well-deWned sample of patients with
advanced oral and oropharyngeal cancer. Deteriorated
HRQOL and functional status before treatment have
been reported in earlier studies, albeit for less well deW-
ned patient groups [9–15]. The results of the present
study indicate a wide range of HRQOL and functional
deWcits in patients with advanced oral and oropharyn-
geal cancer before treatment. Impaired speech and oral
function, as assessed objectively, was associated signiW-
cantly with self-reported global HRQOL and speech
problems, which is in accordance with the conclusions
of Rogers et al. and Karnell et al. [14, 24].
Compared to the general population, patients
scored signiWcantly worse on 5 of 15 scales or items of
the EORTC QLQ-C30 but, conversely, they scored
signiWcantly better on four others. Regarding the
QLQ-H&N35, patients scored signiWcantly worse on
most scales or items but signiWcantly better on cough-
ing and feeling ill. The signiWcantly better scores for
patients compared to the reference groups on some
scales or items may be explained by the fact that peo-
ple from the general population may have (other)
chronic conditions as well. Alonso et al. [25] reported
that, 55% of the general population has one chronic
health condition, and 30% has more than one chronic
condition. They also found that comorbidity can have a
substantial impact on HRQOL, and stated that the
presence of comorbidity limits the ability to attribute
HRQOL deWcits to one speciWc disease (e.g., to head
and neck cancer).
In head and neck cancer patients, comorbidity has
proven to be an important factor associated with
Table 3 Functional status tests for tumour site, tumour stage and comorbidity
Tumour site Tumour stage Comorbidity
Oral cavity Oropharynx T2 T3–T4 No Yes
Mean (SD) 
n =3 7
Mean (SD) 
n =3 9
P Mean (SD) 
n =3 2
Mean (SD) 
n =4 4
P Mean (SD) 
n =2 9
Mean (SD) 
n =4 7
P
Speech
Intelligibility
(0–10) 6.0 (1.3) 6.7 (1.0) 0.015 6.8 (1.0) 6.0 (1.2) 0.011 6.6 (1.0) 6.2 (1.3) 0.132
Articulation
(0–4) 3.4 (0.8) 3.7 (0.6) 0.039 3.8 (0.4) 3.3 (0.8) 0.003 3.8 (0.4) 3.4 (0.8) 0.043
Nasality
(0–4) 3.6 (0.6) 3.8 (0.4) 0.040 3.8 (0.4) 3.7 (0.6) 0.911 3.7 (0.4) 3.7 (0.5) 0.771
n =3 8 n =4 2 n =3 5 n =4 5 n =3 2 n =4 8
Rate
Words per minute 183 (31.6) 182 (38.5) 0.988 189 (33.8) 178 (35.8) 0.201 189 (31.4) 179 (38.1) 0.233
n =3 8 n =4 2 n =3 5 n =4 5 n =3 2 n =4 8
Oral functions
Mobility
Tongue (0–100) 82.3 (20.0) 96.4 (5.4) 0.000 96.0 (5.8) 84.8 (19.3) 0.001 93.9 (9.9) 89.9 (14.4) 0.209
Lip (0–100) 87.4 (5.7) 99.7 (0.9) 0.009 99.4 (2.0) 98.0 (5.1) 0.140 99.3 (2.2) 98.5 (3.9) 0.239
Diadoch (0–100) 87.4 (20.7) 97.2 (6.1) 0.004 97.5 (5.0) 88.7 (19.6) 0.012 97.4 (5.1) 91.5 (15.4) 0.026
Strength
Tongue (0–0.5) 0.2 (0.2) 0.4 (0.2) 0.001 0.4 (0.2) 0.3 (0.2) 0.021 0.4 (0.2) 0.2 (0.2) 0.045
Lip (0–0.5) 0.3 (0.1) 0.4 (0.2) 0.328 0.4 (0.2) 0.3 (0.1) 0.018 0.4 (0.2) 0.3 (0.1) 0.370656 Eur Arch Otorhinolaryngol (2007) 264:651–657
123
complications and mortality rates [26–29]. Studies on
the impact of comorbidity on functional status in head
and neck cancer patients are lacking. Studies that have
examined the impact of comorbid status on HRQOL
are scarce, have yielded conXicting results, and have
examined the post-treatment period only. Pourel et al.
[17] found no signiWcant association between comor-
bidity and HRQOL in 113 long-term survivors 2 years
after treatment for oropharyngeal carcinomas. Simi-
larly, Taylor et al. [30] found no impact of comorbidity
on work-related disability among 384 patients after
treatment for head and neck cancer. However, Terrel
et al. [19] in a study on HRQOL of 570 head and neck
cancer patients after treatment, reported a clear eVect
of comorbidity in patients with two or more comorbid
conditions. In our study on patients with oral or oro-
pharyngeal carcinomas before treatment, comorbidity
was present in 60% of the patients, and proved to have
a major impact on HRQOL and functional status.
Patients with comorbidity had signiWcantly worse
scores on several general and head and neck speciWc
quality of life aspects and on speech and oral function
tests compared to patients without comorbidity.
Unfortunately, the cause of comorbidity was not sys-
tematically noted in the present study; future studies
may provide more insight into the relation between the
cause of comorbidity and HRQOL.
The impact of tumor site and classiWcation on
HRQOL appeared to be limited, with patients with
oral cavity tumors reporting more pain, and patients
with T3–T4 tumors reporting more trouble opening the
mouth and feeling more ill. With regard to tumor site,
comparisons with earlier studies are diYcult because
most studies included patients with oral cavity tumors
only or reported on heterogeneous samples not strati-
Wed by (sub)sites [4, 9–11]. Regarding tumor classiWca-
tion, other studies have reported worse HRQOL for
patients with higher tumor classiWcations and stages
before treatment [2, 14].
Tumor site and classiWcation were found to have a
clear impact on functional status. Patients with oral
cavity tumors (versus oropharyngeal tumors) and
patients with T3–T4 tumors (versus T2 tumors) had
worse speech and oral function scores, which is in
accordance with the results of earlier studies [13, 14].
In conclusion, we observed compromised HRQOL
and functional deWcits among patients with advanced
oral and oropharyngeal cancer before the start of treat-
ment. In addition to the impact of tumor site and classi-
Wcation, comorbidity proved to have a major impact on
HRQOL and functional status. Prospective studies are
needed to obtain insight into the relation between pre-
treatment HRQOL and functional status and outcome
after treatment, and the relationship between changes
in HRQOL and functioning over time and tumor site,
tumor classiWcation, and comorbid conditions.
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